TOL-463 Phase 2 Study for Vaginitis

NCT ID: NCT02866227

Last Updated: 2018-03-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-15
• Study Completion Date: 2017-06-10

Brief Summary

This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.

Detailed Description

This is a Phase II randomized single blind safety and efficacy study of TOL-463, administered to female adults to treat vaginitis. Participants will be randomly assigned (1:1) to dose TOL-463 Gel or TOL-463 Insert. Study medication will be administered vaginally, once nightly for seven days. The duration of the study for each participant will be approximately 21-30 days.

Conditions

Bacterial Vaginosis; Vulvovaginal Candidiasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

BV and/or VVC infection - Gel Treatment

Randomized 1:1 to gel nightly for 7 days. N = 40

Group Type: EXPERIMENTAL

TOL-463

Intervention Type: DRUG

TOL-463 vaginal gel

BV and/or VVC infection - Vaginal Insert Treatment

Randomized 1:1 to insert nightly for 7 days. N = 40

Group Type: EXPERIMENTAL

TOL-463

Intervention Type: DRUG

TOL-463 vaginal insert

Interventions

TOL-463

TOL-463 vaginal gel

Intervention Type: DRUG

TOL-463

TOL-463 vaginal insert

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of bacterial vaginosis based on the presence of all four Amsel criteria.*

• Homogeneous vaginal discharge (off white, milky or gray, thin), positive KOH whiff test, vaginal secretions pH of > 4.5, clue cells > /= 20 percent of vaginal squamous epithelial cells on saline "wet mount"

2. Diagnosis of VVC based on the presence of pseudohyphae on KOH preparation; must also have at least one sign and one symptom*, each rated based on severity** with minimum composite score of 2.

• Signs include vulvovaginal edema, erythema, and/or excoriation. Symptoms include vulvovaginal itching, burning, and/or irritation. **Severity will be graded on a scale of 0-3 (absent = 0; mild = 1; moderate = 2; severe = 3).

3. Participant is willing and able to provide written informed consent.

4. Participant is 18-50 years of age.

5. Participant is in general good health based on medical history, physical examination, vital signs, and pelvic examination.

6. Any Pap test performed in the prior 3 years must be normal or ASCUS HPV negative.*

• Consistent with current Pap screening guidelines, a Pap smear must be performed at Visit 1 for any participant who meets the following criteria and cannot provide documentation (which can include self-report) of a normal or ASCUS HPV negative Pap test within the prior 3 years: is 21 years of age or older and (a) has not had a hysterectomy or (b) has had a hysterectomy and has a history of cervical intraepithelial neoplasia grade 2+ (CIN2+) in the past 20 years. If a Pap smear is conducted at Visit 1, the results are not required prior to enrollment.

7. Participant must have a negative urine pregnancy test at study enrollment.

8. Participant must agree to abstain from sexual intercourse during the seven days of study medication use.

9. Participant must be of non-childbearing potential* or must be using highly effective birth control** to avoid becoming pregnant from the time period noted below prior to and through the end of study treatment.

• Non-childbearing potential is defined as being post-menopausal for at least 1 year, status after bilateral tubal ligation for at least 1 year, or status after bilateral oophorectomy or status after hysterectomy.

• Acceptable methods of birth control include use of hormonal contraceptives from 30 days prior to study drug dosing or having been abstinent from vaginal sexual intercourse from 21 days prior to study drug dosing and agreeing to abstain from oral, anal, and vaginal sexual intercourse during study drug dosing and, if sexually active, use of non-lubricated condoms (in addition to hormonal contraception) for the remainder of the study through the final visit (V3). Intravaginal or intrauterine contraceptives and contraceptive devices are not acceptable forms of birth control for this study.

10. Participant is willing and able to cooperate to the extent and degree required by this protocol at the discretion of the investigator.

11. Participant is willing to refrain from douching and applying any intravaginal products/medications* throughout the course of the trial.

• e.g., antifungal preparations, deodorant sprays, spermicides, contraceptive creams, gels, foams, sponges

12. Participant is willing to refrain from using tampons and diaphragms for the seven days of the study product use.

Exclusion Criteria

1. A diagnosis of vaginitis other than BV or VVC or another vaginal or vulvar condition* that might confuse interpretation of response to study product.

• Examples of such conditions include erosive lichen planus, desquamative interstitial vaginitis, or contact dermatitis involving the vulvar epithelium.

2. Presence of T. vaginalis on wet mount or evidence of other infectious cause of cervicitis or vaginitis on physical examination.

3. Active genital lesions, including ulcers, vesicles consistent with herpes, or warts.

4. Use of metronidazole or other 5-nitro-imidazole derivative or clindamycin or an antifungal agent (intravaginal or systemic) for the treatment of any condition within 14 days of start of study.

5. Planned ongoing immunosuppressive therapy or systemic antibiotic treatment during the course of the study.

6. Use of any investigational drug within 30 days prior to screening.

7. History of hypersensitivity to any ingredient in the formulations.

8. Women with cervical intraepithelial neoplasia (CIN) or cervical carcinoma.

9. Currently breastfeeding.

10. Menstruating at the time of diagnosis.*

• Women menstruating at the time of diagnosis may be rescreened at a later time.

11. Any other condition that, in the opinion of the investigator, would interfere with participation in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Toltec Pharmaceuticals, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Alabama at Birmingham School of Medicine- Infectious Disease

Birmingham, Alabama, United States

University of Washington - Harborview Medical Center - Center for AIDS and STD

Seattle, Washington, United States

Countries

United States

References

Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis. 2019 Feb 15;68(5):803-809. doi: 10.1093/cid/ciy554.

Reference Type: DERIVED

PMID: 30184181 (View on PubMed)

Other Identifiers

HHSN272201300012I

Identifier Type: -

Identifier Source: secondary_id

15-0039

Identifier Type: -

Identifier Source: org_study_id